(Adnkronos) – Supportando la nuova campagna di sensibilizzazione dedicata al carcinoma mammario metastatico triplo negativo, Gilead Sciences conferma il suo impegno nella ricerca contro i tumori. L’obiettivo è avere 10 terapie trasformative entro il 2030.
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.